Roche drug improves lung function in patients with uncontrolled asthma, study finds
BASEL, Switzerland — An investigational treatment made by Roche for asthma increased lung function in patients who could not adequately control their disease with inhaled corticosteroids, according to results of a mid-stage clinical trial.
Results of the phase-2 "MILLY" study of lebrikizumab were published last week in the New England Journal of Medicine. The drug is a humanized monoclonal antibody designed to block interleukin-13 cytokine, a key contributor to asthma that also increases levels of the protein periostin, which can be measured with a blood test.
"The findings of the MILLY study and the development of a potential biomarker have shown that we may be able to select appropriate asthma patients for lebrikizumab therapy," said Richard Scheller, EVP Genentech Research and Early Development, a division of Roche. "These results support further investigation of lebrikizumab as a personalized medicine for patients who suffer from moderate to severe uncontrolled asthma."
Single-ingredient acetaminophen for kids hits store shelves
WASHINGTON — Uniform concentrations of single-ingredient liquid pediatric acetaminophen medicines have been making their way to the shelf as promised by the Consumer Healthcare Products Association earlier this year, as evidenced by these new product facings from PediaCare and Triaminic. Note, too, that both new formulations feature uniform age-appropriate dosing devices, in this case syringes.
It’s just another example of how the consumer healthcare association proactively addresses concerns in the industry.
Boston Therapeutics files for approval of generic diabetes drug
MANCHESTER, N.H. — Boston Therapeutics is seeking approval for a generic version of a pill for Type 2 diabetes, the drug maker said.
Boston Therapeutics announced that it had filed an application with the Food and Drug Administration for chewable metformin tablets. The drug is a version of Bristol-Myers Squibb’s Glucophage.
"Metformin is one of the most widely prescribed diabetes drugs in the world, and our neural chemistry polysaccharide formulation will benefit prediabetic and diabetic patients," Boston Therapeutics CEO David Platt said. "This new option in treatments fits into our pipeline of other diabetes therapeutics, including Ipoxyn for limb ischemia and PAZ-320 for blood glucose management."